Verseon Corporation Verseon presents data on DME program at BIO 2017
June 26 2017 - 2:00AM
RNS Non-Regulatory
TIDMVSN
Verseon Corporation
26 June 2017
Press release June 26, 2017
Verseon Corporation
("Verseon" or the "Company")
Verseon presents preclinical data on diabetic macular edema
candidates at BIO 2017
Fremont, Calif.-Verseon presented pharmacokinetic and in vivo
efficacy data on its diabetic macular edema (DME) candidates at the
2017 BIO International Conference last week. The data suggest that
Verseon's drug candidates reduce leakage into the retina and are
suitable for topical or oral dosing.
Verseon is developing plasma kallikrein inhibitors for the
treatment of DME, a major cause of vision loss in persons with
diabetes mellitus. Weakened blood vessels caused by chronically
high blood sugar can lead to fluid leaking into the retina, which
may result in swelling, blurred vision, and eventually central
vision loss associated with DME. By targeting the serine protease
plasma kallikrein, a validated disease pathway, Verseon's drug
candidates treat an underlying cause of DME.
At the BIO conference, Verseon presented an in vivo efficacy
study with systemic dosing, which indicates that the Company's drug
candidates reduce leakage into the retina and decrease mean
circulation times, suggesting a slowing of the disease progression.
Dr. David Kita, Vice President of R&D at Verseon, also
presented pharmacokinetics for two series of drug candidates, which
show good exposure in the relevant tissues of the eye when
administered topically. Some of the Company's candidates also show
high oral bioavailability.
A second presentation covered recent preclinical results in
Verseon's anticoagulation program. The Company showed efficacy and
safety data for its first development candidate for clinical trials
and presented preclinical data on another promising lead candidate
with a distinct chemotype.
About Verseon's diabetic macular edema program
Verseon has developed a new class of potent, selective compounds
for the treatment of diabetic macular edema. The Company's plasma
kallikrein inhibitors target a validated pathway addressing an
underlying cause of the disease. In preclinical testing, Verseon's
inhibitors show favorable biochemical properties permitting either
oral or topical (eye drop) administration.
About Verseon's anticoagulation program
Verseon's potent, highly selective, oral direct thrombin
inhibitors act through reversible covalent inhibition, a unique
mode of action. Preclinical studies show that Verseon's inhibitors
act as effective anticoagulants in multiple efficacy studies, but
do not disrupt platelet function. This unique feature could explain
their observed low bleeding risk. One of Verseon's lead candidates
furthermore shows very low renal clearance, a highly desirable
property for patients with impaired renal function.
About Verseon
Verseon Corporation (www.verseon.com, AIM: VSN) is a
technology-based pharmaceutical company that employs its
proprietary, computational drug discovery platform to develop novel
therapeutics that are unlikely to be found using conventional
methods. The Company is applying its platform to a growing drug
pipeline and currently has three active drug programs in the areas
of anticoagulation, diabetic macular edema, and oncology.
-Ends-
For further information, please contact
Verseon Corporation www.verseon.com
+1 (510) 225
Tina Schlafly 9000
Cenkos Securities (NOMAD and
Joint Broker)
+44 (0) 20
Neil McDonald / Beth McKiernan 7397 8900
Cantor Fitzgerald Europe (Joint
Broker)
Marc Milmo / Phil Davies / +44 (0) 20
Callum Butterfield 7894 7000
Mirabaud Securities LLP (Joint
Broker)
+44 (0) 20
Peter Krens 7321 2508
For financial and business media enquiries, please contact
Buchanan Communications Ltd
(PR Advisers)
Henry Harrison-Topham / Jamie +44 (0) 20
Hooper 7466 5000
For trade and pharma media enquiries, please contact
Vane Percy & Roberts
+44 (0) 1737
Simon Vane Percy 821 890
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends, " "estimates,"
"plans," "will," "outlook," and similar expressions.
Forward-looking statements are based on management's current plans,
estimates, assumptions, and projections, and speak only as of the
date they are made. We undertake no obligation to update any
forward-looking statement in light of new information or future
events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which
are difficult to predict and are generally beyond our control.
Actual results or outcomes may differ materially from those implied
by the forward-looking statements as a result of the impact of a
number of factors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFMGZVLKLGNZG
(END) Dow Jones Newswires
June 26, 2017 02:00 ET (06:00 GMT)
Verseon (LSE:VSN)
Historical Stock Chart
From Apr 2024 to May 2024
Verseon (LSE:VSN)
Historical Stock Chart
From May 2023 to May 2024